IB 
Union Calendar No. 47 
118TH CONGRESS 
1ST SESSION 
H. R. 467 
[Report No. 118–67, Part I] 
To amend the Controlled Substances Act with respect to the scheduling 
of fentanyl-related substances, and for other purposes. 
IN THE HOUSE OF REPRESENTATIVES 
JANUARY 24, 2023 
Mr. GRIFFITH (for himself, Mr. LATTA, Mrs. RODGERS of Washington, Mr. 
GUTHRIE, Mr. BILIRAKIS, Mr. BUCSHON, Mr. HUDSON, Mr. BURGESS, 
Mr. CARTER of Georgia, Mr. DUNCAN, Mr. DUNN of Florida, Mr. CREN-
SHAW, 
Mr. 
JOYCE
of 
Pennsylvania, 
Mr. 
BALDERSON, 
Mrs. 
HARSHBARGER, Mrs. MILLER-MEEKS, Mrs. CAMMACK, Mr. ALLEN, Mr. 
WALBERG, Mr. CURTIS, Mr. PALMER, Mr. BUCHANAN, Mr. BANKS, Mr. 
FITZGERALD, and Mr. MOONEY) introduced the following bill; which was 
referred to the Committee on Energy and Commerce, and in addition to 
the Committee on the Judiciary, for a period to be subsequently deter-
mined by the Speaker, in each case for consideration of such provisions 
as fall within the jurisdiction of the committee concerned 
MAY 17, 2023 
Additional sponsors: Mr. PFLUGER, Mr. ARMSTRONG, Mr. PENCE, Mr. AUS-
TIN SCOTT of Georgia, Mr. OBERNOLTE, Mr. WOMACK, Mr. EDWARDS, 
Mr. FINSTAD, Mr. CARL, Mrs. LESKO, Mr. MIKE GARCIA of California, 
Mr. CISCOMANI, Mr. CLINE, Mrs. BICE, Mr. CARTER of Texas, Mr. 
MOOLENAAR, Mr. ROGERS of Kentucky, Mr. BEAN of Florida, Mr. 
MEUSER, Mr. BOST, Mr. BARR, Mr. VAN DREW, Mr. D’ESPOSITO, Mrs. 
MILLER of West Virginia, Mrs. CHAVEZ-DEREMER, Mr. WESTERMAN, 
Mr. LANGWORTHY, and Mr. BURCHETT 
MAY 17, 2023 
Reported from the Committee on Energy and Commerce with an amendment 
[Strike out all after the enacting clause and insert the part printed in italic] 
VerDate Sep 11 2014 
00:56 May 18, 2023
Jkt 039200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6652
E:\BILLS\H467.RH
H467
kjohnson on DSK79L0C42PROD with BILLS
MAY 17, 2023 
Committee on the Judiciary discharged; committed to the Committee of the 
Whole House on the State of the Union and ordered to be printed 
[For text of introduced bill, see copy of bill as introduced on January 24, 2023] 
A BILL 
To amend the Controlled Substances Act with respect to 
the scheduling of fentanyl-related substances, and for 
other purposes. 
VerDate Sep 11 2014 
00:56 May 18, 2023
Jkt 039200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6652
E:\BILLS\H467.RH
H467
kjohnson on DSK79L0C42PROD with BILLS
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘Halt All Lethal Traf-
ficking of Fentanyl Act’’ or the ‘‘HALT Fentanyl Act’’. 
SEC. 2. CLASS SCHEDULING OF FENTANYL-RELATED SUB-
STANCES. 
Section 202(c) of the Controlled Substances Act (21 
U.S.C. 812(c)) is amended by adding at the end of schedule 
I the following: 
‘‘(e)(1) Unless specifically exempted or unless listed in 
another schedule, any material, compound, mixture, or 
preparation which contains any quantity of a fentanyl-re-
lated substance, or which contains the salts, isomers, and 
salts of isomers of a fentanyl-related substance whenever the 
existence of such salts, isomers, and salts of isomers is pos-
sible within the specific chemical designation. 
‘‘(2) For purposes of paragraph (1), except as provided 
in paragraph (3), the term ‘fentanyl-related substance’ 
means any substance that is structurally related to fentanyl 
by 1 or more of the following modifications: 
‘‘(A) By replacement of the phenyl portion of the 
phenethyl group by any monocycle, whether or not 
further substituted in or on the monocycle. 
VerDate Sep 11 2014 
00:56 May 18, 2023
Jkt 039200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6203
E:\BILLS\H467.RH
H467
kjohnson on DSK79L0C42PROD with BILLS
‘‘(B) By substitution in or on the phenethyl 
group with alkyl, alkenyl, alkoxyl, hydroxyl, halo, 
haloalkyl, amino, or nitro groups. 
‘‘(C) By substitution in or on the piperidine 
ring with alkyl, alkenyl, alkoxyl, ester, ether, 
hydroxyl, halo, haloalkyl, amino, or nitro groups. 
‘‘(D) By replacement of the aniline ring with 
any aromatic monocycle whether or not further sub-
stituted in or on the aromatic monocycle. 
‘‘(E) By replacement of the N–propionyl group 
with another acyl group. 
‘‘(3) A substance that satisfies the definition of the 
term ‘fentanyl-related substance’ in paragraph (2) shall 
nonetheless not be treated as a fentanyl-related substance 
subject to this schedule if the substance— 
‘‘(A) is controlled by action of the Attorney Gen-
eral under section 201; or 
‘‘(B) is otherwise expressly listed in a schedule 
other than this schedule. 
‘‘(4)(A) The Attorney General may by order publish 
in the Federal Register a list of substances that satisfy the 
definition of the term ‘fentanyl-related substance’ in para-
graph (2). 
‘‘(B) The absence of a substance from a list published 
under subparagraph (A) does not negate the control status 
VerDate Sep 11 2014 
00:56 May 18, 2023
Jkt 039200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6203
E:\BILLS\H467.RH
H467
kjohnson on DSK79L0C42PROD with BILLS
of the substance under this schedule if the substance satisfies 
the definition of the term ‘fentanyl-related substance’ in 
paragraph (2).’’. 
SEC. 3. REGISTRATION REQUIREMENTS RELATED TO RE-
SEARCH. 
(a) ALTERNATIVE
REGISTRATION
PROCESS
FOR 
SCHEDULE I RESEARCH.—Section 303 of the Controlled 
Substances Act (21 U.S.C. 823) is amended— 
(1) by redesignating the second subsection (l) (re-
lating to required training for prescribers) as sub-
section (m); and 
(2) by adding at the end the following: 
‘‘(n) SPECIAL PROVISIONS FOR PRACTITIONERS CON-
DUCTING CERTAIN RESEARCH WITH SCHEDULE I CON-
TROLLED SUBSTANCES.— 
‘‘(1) IN GENERAL.—Notwithstanding subsection 
(f), a practitioner may conduct research described in 
paragraph (2) of this subsection with 1 or more 
schedule I substances in accordance with subpara-
graph (A) or (B) of paragraph (3) of this subsection. 
‘‘(2) RESEARCH SUBJECT TO EXPEDITED PROCE-
DURES.—Research described in this paragraph is re-
search that— 
‘‘(A) is with respect to a drug that is the 
subject of an investigational use exemption under 
VerDate Sep 11 2014 
00:56 May 18, 2023
Jkt 039200
PO 00000
Frm 00005
Fmt 6652
Sfmt 6203
E:\BILLS\H467.RH
H467
kjohnson on DSK79L0C42PROD with BILLS
section 505(i) of the Federal Food, Drug, and 
Cosmetic Act; or 
‘‘(B) is— 
‘‘(i) conducted by the Department of 
Health and Human Services or the Depart-
ment of Veterans Affairs; or 
‘‘(ii) funded partly or entirely by a 
grant, contract, cooperative agreement, or 
other transaction from the Department of 
Health and Human Services or the Depart-
ment of Veterans Affairs. 
‘‘(3) EXPEDITED PROCEDURES.— 
‘‘(A) 
RESEARCHER
WITH
A
CURRENT 
SCHEDULE I OR II RESEARCH REGISTRATION.— 
‘‘(i) IN GENERAL.—If a practitioner is 
registered to conduct research with a con-
trolled substance in schedule I or II, the 
practitioner may conduct research under 
this subsection on and after the date that is 
30 days after the date on which the practi-
tioner sends a notice to the Attorney Gen-
eral containing the following information, 
with respect to each substance with which 
the practitioner will conduct the research: 
VerDate Sep 11 2014 
00:56 May 18, 2023
Jkt 039200
PO 00000
Frm 00006
Fmt 6652
Sfmt 6203
E:\BILLS\H467.RH
H467
kjohnson on DSK79L0C42PROD with BILLS
‘‘(I) The chemical name of the 
substance. 
‘‘(II) The quantity of the sub-
stance to be used in the research. 
‘‘(III) Demonstration that the re-
search is in the category described in 
paragraph (2), which demonstration 
may be satisfied— 
‘‘(aa) in the case of a grant, 
contract, cooperative agreement, 
or other transaction, or intra-
mural research project, by identi-
fying the sponsoring agency and 
supplying the number of the 
grant, contract, cooperative agree-
ment, 
other 
transaction, 
or 
project; or 
‘‘(bb) in the case of an appli-
cation under section 505(i) of the 
Federal Food, Drug, and Cosmetic 
Act, by supplying the application 
number and the sponsor of record 
on the application. 
‘‘(IV) Demonstration that the re-
searcher is authorized to conduct re-
VerDate Sep 11 2014 
00:56 May 18, 2023
Jkt 039200
PO 00000
Frm 00007
Fmt 6652
Sfmt 6203
E:\BILLS\H467.RH
H467
kjohnson on DSK79L0C42PROD with BILLS
search with respect to the substance 
under the laws of the State in which 
the research will take place. 
‘‘(ii) VERIFICATION
OF
INFORMATION 
BY HHS OR VA.—Upon request from the At-
torney General, the Secretary of Health and 
Human Services or the Secretary of Vet-
erans Affairs, as appropriate, shall verify 
information submitted by an applicant 
under clause (i)(III). 
‘‘(B) RESEARCHER
WITHOUT
A
CURRENT 
SCHEDULE I OR II RESEARCH REGISTRATION.— 
‘‘(i) IN GENERAL.—If a practitioner is 
not registered to conduct research with a 
controlled substance in schedule I or II, the 
practitioner may send a notice to the Attor-
ney General containing the information 
listed in subparagraph (A)(i), with respect 
to each substance with which the practi-
tioner will conduct the research. 
‘‘(ii) ATTORNEY
GENERAL
ACTION.— 
The Attorney General shall— 
‘‘(I) treat notice received under 
clause (i) as a sufficient application 
for a research registration; and 
VerDate Sep 11 2014 
00:56 May 18, 2023
Jkt 039200
PO 00000
Frm 00008
Fmt 6652
Sfmt 6203
E:\BILLS\H467.RH
H467
kjohnson on DSK79L0C42PROD with BILLS
‘‘(II) not later than 45 days of re-
ceiving such a notice that contains all 
information required under subpara-
graph (A)(i)— 
‘‘(aa) register the applicant; 
or 
‘‘(bb) serve an order to show 
cause upon the applicant in ac-
cordance with section 304(c). 
‘‘(4) ELECTRONIC SUBMISSIONS.—The Attorney 
General shall provide a means to permit a practi-
tioner to submit a notification under paragraph (3) 
electronically. 
‘‘(5) LIMITATION ON AMOUNTS.—A practitioner 
conducting research with a schedule I substance under 
this subsection may only possess the amounts of 
schedule I substance identified in— 
‘‘(A) the notification to the Attorney Gen-
eral under paragraph (3); or 
‘‘(B) a supplemental notification that the 
practitioner may send if the practitioner needs 
additional amounts for the research, which sup-
plemental notification shall include— 
‘‘(i) the name of the practitioner; 
VerDate Sep 11 2014 
00:56 May 18, 2023
Jkt 039200
PO 00000
Frm 00009
Fmt 6652
Sfmt 6203
E:\BILLS\H467.RH
H467
kjohnson on DSK79L0C42PROD with BILLS
‘‘(ii) the additional quantity needed of 
the substance; and 
‘‘(iii) an attestation that the research 
to be conducted with the substance is con-
sistent with the scope of the research that 
was the subject of the notification under 
paragraph (3). 
‘‘(6) IMPORTATION AND EXPORTATION REQUIRE-
MENTS NOT AFFECTED.—Nothing in this subsection 
alters the requirements of part A of title III, regard-
ing the importation and exportation of controlled sub-
stances.’’. 
(b) SEPARATE REGISTRATIONS NOT REQUIRED FOR 
ADDITIONAL RESEARCHER IN SAME INSTITUTION.—Sec-
tion 302(c) of the Controlled Substances Act (21 U.S.C. 
822(c)) is amended by adding at the end the following: 
‘‘(4) An agent or employee of a research institu-
tion that is conducting research with a controlled sub-
stance if— 
‘‘(A) the agent or employee is acting within 
the scope of the professional practice of the agent 
or employee; 
‘‘(B) another agent or employee of the insti-
tution is registered to conduct research with a 
controlled substance in the same schedule; 
VerDate Sep 11 2014 
00:56 May 18, 2023
Jkt 039200
PO 00000
Frm 00010
Fmt 6652
Sfmt 6203
E:\BILLS\H467.RH
H467
kjohnson on DSK79L0C42PROD with BILLS
‘‘(C) the researcher who is so registered— 
‘‘(i) informs the Attorney General of 
the name, position title, and employing in-
stitution of the agent or employee who is 
not separately registered; 
‘‘(ii) authorizes that agent or employee 
to perform research under the registration of 
the registered researcher; and 
‘‘(iii) affirms that any act taken by 
that agent or employee involving a con-
trolled substance shall be attributable to the 
registered researcher, as if the researcher 
had directly committed the act, for purposes 
of any proceeding under section 304(a) to 
suspend or revoke the registration of the reg-
istered researcher; and 
‘‘(D) the Attorney General does not, within 
30 days of receiving the information, authoriza-
tion, and affirmation described in subparagraph 
(C), refuse, for a reason listed in section 304(a), 
to allow the agent or employee to possess the sub-
stance without a separate registration.’’. 
(c) SINGLE REGISTRATION FOR RELATED RESEARCH 
SITES.—Section 302(e) of the Controlled Substances Act (21 
VerDate Sep 11 2014 
00:56 May 18, 2023
Jkt 039200
PO 00000
Frm 00011
Fmt 6652
Sfmt 6203
E:\BILLS\H467.RH
H467
kjohnson on DSK79L0C42PROD with BILLS
U.S.C. 822(e)) is amended by adding at the end the fol-
lowing: 
‘‘(4)(A) Notwithstanding paragraph (1), a person reg-
istered to conduct research with a controlled substance 
under section 303(f) may conduct the research under a sin-
gle registration if— 
‘‘(i) the research occurs exclusively on sites all of 
which are— 
‘‘(I) within the same city or county; and 
‘‘(II) under the control of the same institu-
tion, organization, or agency; and 
‘‘(ii) before commencing the research, the re-
searcher notifies the Attorney General of each site 
where— 
‘‘(I) the research will be conducted; or 
‘‘(II) the controlled substance will be stored 
or administered. 
‘‘(B) A site described in subparagraph (A) shall be in-
cluded in a registration described in that subparagraph 
only if the researcher has notified the Attorney General of 
the site— 
‘‘(i) in the application for the registration; or 
‘‘(ii) before the research is conducted, or before 
the controlled substance is stored or administered, at 
the site. 
VerDate Sep 11 2014 
00:56 May 18, 2023
Jkt 039200
PO 00000
Frm 00012
Fmt 6652
Sfmt 6203
E:\BILLS\H467.RH
H467
kjohnson on DSK79L0C42PROD with BILLS
‘‘(C) The Attorney General may, in consultation with 
the Secretary, issue regulations addressing, with respect to 
research sites described in subparagraph (A)— 
‘‘(i) the manner in which controlled substances 
may be delivered to the research sites; 
‘‘(ii) the storage and security of controlled sub-
stances at the research sites; 
‘‘(iii) the maintenance of records for the research 
sites; and 
‘‘(iv) any other matters necessary to ensure effec-
tive controls against diversion at the research sites.’’. 
(d) NEW INSPECTION NOT REQUIRED IN CERTAIN SIT-
UATIONS.—Section 302(f) of the Controlled Substances Act 
(21 U.S.C. 822(f)) is amended— 
(1) by striking ‘‘(f) The’’ and inserting ‘‘(f)(1) 
The’’; and 
(2) by adding at the end the following: 
‘‘(2)(A) If a person is registered to conduct research 
with a controlled substance and applies for a registration, 
or for a modification of a registration, to conduct research 
with a second controlled substance that is in the same sched-
ule as the first controlled substance, or is in a schedule with 
a higher numerical designation than the schedule of the first 
controlled substance, a new inspection by the Attorney Gen-
eral of the registered location is not required. 
VerDate Sep 11 2014 
00:56 May 18, 2023
Jkt 039200
PO 00000
Frm 00013
Fmt 6652
Sfmt 6203
E:\BILLS\H467.RH
H467
kjohnson on DSK79L0C42PROD with BILLS
‘‘(B) Nothing in subparagraph (A) shall prohibit the 
Attorney General from conducting an inspection that the 
Attorney General determines necessary to ensure that a reg-
istrant maintains effective controls against diversion.’’. 
(e) CONTINUATION
OF RESEARCH
ON SUBSTANCES 
NEWLY ADDED TO SCHEDULE I.—Section 302 of the Con-
trolled Substances Act (21 U.S.C. 822) is amended by add-
ing at the end the following: 
‘‘(h) CONTINUATION OF RESEARCH ON SUBSTANCES 
NEWLY ADDED TO SCHEDULE I.—If a person is conducting 
research on a substance when the substance is added to 
schedule I, and the person is already registered to conduct 
research with a controlled substance in schedule I— 
‘‘(1) not later than 90 days after the scheduling 
of the newly scheduled substance, the person shall sub-
mit a completed application for registration or modi-
fication of existing registration, to conduct research 
on the substance, in accordance with regulations 
issued by the Attorney General for purposes of this 
paragraph; 
‘‘(2) the person may, notwithstanding sub-
sections (a) and (b), continue to conduct the research 
on the substance until— 
‘‘(A) the person withdraws the application 
described in paragraph (1) of this subsection; or 
VerDate Sep 11 2014 
00:56 May 18, 2023
Jkt 039200
PO 00000
Frm 00014
Fmt 6652
Sfmt 6203
E:\BILLS\H467.RH
H467
kjohnson on DSK79L0C42PROD with BILLS